News
Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...
Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...
NEW YORK (AP) — Stocks are rising on Wall Street Thursday, even as President Donald Trump’s latest tariffs kicked into effect ...
Asianet Newsable on MSN36m
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback